MATZ MARILYN sold $428K of TER

MATZ MARILYN sold 1,200 shares of TERADYNE, INC (TER) at $356.31 ($0.43M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MATZ MARILYN
Published Jul 16, 2026, 5:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TER
Neutral
high confidence
Mentioned
$TER
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TERNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price ($356.31/share), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and lack of additional fundamental information suggest limited trading edge.

03

What to watch

The article does not state whether the director’s sale was part of a larger series, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-16, covering a sale executed 2026-07-15.

Background

The article is a SEC Form 4 insider transaction disclosure for Teradyne, Inc.

Company-level read

Ticker impact

$TERNeutralHigh confidence
Context

Teradyne director MatZ Marilyn sold 1,200 shares in an open-market transaction on 2026-07-15 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal impact on TER price; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but it specifies an open-market sale and a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector read-across is provided; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management’s view of valuation or liquidity needs, which some traders may still treat as mildly bearish.

Key entities

  • TERADYNE, INC

    Company whose director disclosed an open-market sale of shares via Form 4.

  • MATZ MARILYN

    Director who sold 1,200 shares on 2026-07-15 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TERHigh

Teradyne and FormFactor jump after Jefferies starts coverage with Buy ratings

Jefferies initiated coverage of Teradyne and FormFactor with Buy ratings, citing their roles in AI-driven chip testing. Teradyne's stock rose 8.3% to $265.78, with a $284 target, while FormFactor gained 11.9% with a $102 target. Jefferies projects significant growth in the automated test equipment market, with Teradyne's revenue potentially rising from $1.9B to $6.9B by 2030. Both companies have seen recent pullbacks but reported strong AI-related revenue growth.

$TERHigh

Teradyne's AI testing opportunity prompts Jefferies 'buy' rating

Jefferies initiated coverage of Teradyne (NYSE:TER) with a Buy rating and $284 price target, citing AI-driven demand. The broker forecasts semiconductor testing market growth to $25B by 2030, with Teradyne's SoC testing revenue rising to $6.9B. Teradyne's shares fell 53% from summer highs, which Jefferies sees as an entry point. The bank expects Teradyne to gain market share and benefit from Nvidia's (NASDAQ:NVDA) adoption of dual sourcing.

$TERHigh

Why is Teradyne stock surging today?

Teradyne (TER) stock rose 8% in pre-market trading after Jefferies initiated coverage with a Buy rating and $284 price target, citing AI-driven growth. Analysts expect the semiconductor test equipment market to expand significantly, with TER benefiting from increased system-on-chip testing. The company's Q3 2026 earnings beat consensus, and broader tech sector gains also supported the surge.